Profile
Sector:
HealthcareCountry:
United StatesIPO:
17 March 1980Website:
http://www.viatris.comNext earnings report:
08 August 2024Last dividends:
23 May 2024Next dividends:
N/APrice
regular market | 2 min agoAnalysts recommendations
Institutional Ownership
Included in screeners
VTRS Latest News
Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.
PITTSBURGH , July 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
PITTSBURGH , June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A.
PITTSBURGH , June 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024. Chief Executive Officer Scott A Smith and Company executives will represent the company in a fireside chat scheduled at 9:20 a.m.
PITTSBURGH , June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors.
PITTSBURGH , May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024. Chief Executive Officer Scott A.
Viatris Inc. reported Q1 2024 results in line with expectations, with a 2% decline in net sales. The company's EBITDA and free cash flow have been negatively impacted by declining sales, and its debt to EBITDA ratio remains high. Despite the low P/E ratio, Viatris stock has not delivered significant returns. We go into the reasons why.
Viatris (VTRS) is expected to benefit in Q1 from growth in its branded products and increased revenue from recent product launches.
Viatris (VTRS) has the ideal mix of factors for a potential earnings outperformance in its upcoming report. Be ready with the main predictions.
Viatris Inc. is a deep value pharmaceutical company with a low valuation and a 4.1% yield. Viatris has seen a slowdown in top line decline and has a promising pipeline of potential blockbuster drugs. Management is de-risking the balance sheet and returning capital to shareholders through dividends and share repurchases.
What type of business is Viatris?
Viatris Inc. is an American global pharmaceutical company formed as a result of the merger of Mylan and Upjohn on November 16, 2020. The company's headquarters is located in Canonsburg, Pennsylvania. The company manufactures and sells various types of medications: brand names (such as Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, over-the-counter drugs, and active pharmaceutical ingredients. They cover a wide range of therapeutic areas such as cardiovascular, infectious diseases, oncology, immunology, CNS and anesthesia, women's health, diabetes and metabolism, gastroenterology, respiratory and allergy, dermatology.
What sector is Viatris in?
Viatris is in the Healthcare sector
What industry is Viatris in?
Viatris is in the Drug Manufacturers - Specialty & Generic industry
What country is Viatris from?
Viatris is headquartered in United States
When did Viatris go public?
Viatris initial public offering (IPO) was on 17 March 1980
What is Viatris website?
https://www.viatris.com
Is Viatris in the S&P 500?
Yes, Viatris is included in the S&P 500 index
Is Viatris in the NASDAQ 100?
No, Viatris is not included in the NASDAQ 100 index
Is Viatris in the Dow Jones?
No, Viatris is not included in the Dow Jones index
When does Viatris report earnings?
The next expected earnings date for Viatris is 08 August 2024